At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
AZD3355 +1 moredrug
Likely dose
AZD3355 65 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo Controlled, Randomized, Two Centre Phase IIA Pharmacodynamic Cross-over Study to Assess the Effect of AZD3355, 65 mg Bid, on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in GERD Patients With an Incomplete Response to PPI Treatment
In Brief
A Phase 2 clinical trial evaluating AZD3355 and Placebo for Reflux Episodes. Completed, enrolled 27 participants.
Detailed Summary
The purpose of the study is to compare frequency and content of reflux episodes in patients with gastroesophageal reflux disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReflux Episodes
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
Primary CompletionFeb 2008
First PostedAug 2008
TodayJul 2026
First PostedAug 28, 2008
Enrollment StartFeb 1, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.8 years ago
Interventions
AZD3355drug
65 mg capsules, oral, 3 single doses
Placebodrug
capsules, oral, 3 single doses